Recap of the Original PIVOT-HD Phase 2 Trial (Image Credits: Pixabay)
PTC Therapeutics recently shared encouraging 24-month interim data from its PIVOT-HD long-term extension study, spotlighting votoplam’s potential to alter the course of Huntington’s disease.[1][2] The findings arrive at a pivotal moment, as the therapy – now partnered with Novartis – advances toward a global Phase 3 trial amid a landscape lacking approved disease-modifying treatments for this devastating genetic disorder. Huntington’s affects neuron function through toxic mutant huntingtin protein buildup, leading to progressive motor, cognitive, and behavioral decline, typically starting in mid-adulthood.
Recap of the Original PIVOT-HD Phase 2 Trial
The PIVOT-HD study began as a 12-month placebo-controlled trial evaluating votoplam, an oral small-molecule splicing modifier designed to reduce huntingtin protein levels.[3] Researchers tested two doses – 5 mg and 10 mg daily – in patients with Stage 2 and Stage 3 Huntington’s disease. Primary endpoints focused on blood huntingtin lowering at 12 weeks and overall safety.
Participants who completed the initial phase rolled over into a long-term extension, where all received votoplam. Those originally on placebo were randomized 1:1 to the 5 mg or 10 mg arms, with blinding preserved to original assignments. The trial targeted early-to-mid-stage patients to gauge potential benefits before symptoms become severely disabling.[4]
Striking Dose-Dependent Slowing in Stage 2 Patients
At the 24-month mark, Stage 2 patients – those with milder functional impairment – showed clear dose-dependent benefits on the Composite Unified Huntington’s Disease Rating Scale, or cUHDRS, a key measure of disease progression across motor, cognitive, and functional domains.[1] Compared to a propensity score-matched natural history cohort from the ENROLL-HD registry, the 10 mg group experienced 52% less worsening, while the 5 mg group saw 28% slowing.
These results held across cUHDRS subscales, including total functional capacity and motor scores. The analysis included 21 patients on 5 mg and 24 on 10 mg in Stage 2, with baselines closely matched to the comparator group on factors like age, CAG repeat length, and symptom severity.[2]
| Dose | Stage 2 Patients (N) | cUHDRS Slowing vs. Natural History |
|---|---|---|
| 5 mg | 21 | 28%[2] |
| 10 mg | 24 | 52%[2] |
Emerging Signals in Stage 3 and Biomarker Stability
In Stage 3 patients, where functional capacity dips further, the data hinted at similar trends of reduced progression, though less pronounced than in Stage 2. Mean changes on cUHDRS and related scales suggested potential benefits, warranting closer scrutiny as more data matures.[1]
Biomarkers reinforced the profile. Blood huntingtin levels dropped durably from the original trial – 23% to 39% at 12 months, dose-dependent – with no rebound noted. Plasma neurofilament light chain, a marker of neuronal damage, stayed stable or declined slightly (down 2.4% at 5 mg, 4.1% at 10 mg), bucking the natural upward trajectory in untreated patients.[2]
What matters now: These external comparator analyses, while not randomized controls, provide early real-world context and align with Novartis’s decision to launch Phase 3 INVEST-HD in early-stage patients.
Safety Remains Favorable After Two Years
Votoplam maintained its established tolerability through 24 months. No new adverse event signals emerged across doses or stages. Treatment-emergent adverse events affected 86% to 92% of participants, mostly mild to moderate, with serious events rare (6-7%) and none linked to treatment discontinuations or deaths.[2]
Common issues mirrored those in Huntington’s natural history, such as infections and falls. The absence of neurofilament spikes underscored a lack of neurotoxicity concerns.
“These results give us confidence in the potential for votoplam to deliver long-term meaningful effect on slowing Huntington’s disease progression,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.[1]
Charting the Path Ahead
PTC partnered votoplam with Novartis in December 2024, handing over development reins post-PIVOT-HD. Novartis has since launched the Phase 3 INVEST-HD trial, enrolling about 770 early-stage patients on 10 mg versus placebo, with cUHDRS change at 36 months as the primary endpoint.[3] The companies plan to review these interim findings for possible regulatory discussions.
While interim data carry uncertainties – such as reliance on external controls and smaller Stage 3 numbers – the results build on prior huntingtin reductions and clinical trends. They offer measured optimism for an oral therapy that could one day shift Huntington’s trajectory, pending confirmatory trials.